OMLYCLO secures FDA approval as the first interchangeable biosimilar to XOLAIR, set to be available in multiple dosage strengths to challenge existing market incumbents.
The article announces a biosimilar competitor to Xolair, which is owned by GSK, potentially impacting their market share for this specific drug.
Merck holds the rights to Xolair in certain territories or is a key player in the allergy/asthma space, though the primary focus is on the new entrant OMYLCLO.
The FDA has granted approval to OMLYCLO (omalizumab-igec) as the first interchangeable biosimilar to the blockbuster asthma and allergy drug XOLAIR. This regulatory milestone allows for automatic substitution at the pharmacy level across all four approved indications, potentially increasing market competition for existing manufacturers.
The interchangeable designation allows pharmacists to substitute OMLYCLO for XOLAIR without needing the intervention of the prescribing healthcare provider, subject to state pharmacy laws.